文献速递淋巴瘤

非病毒RNA嵌合抗原受体修饰T细胞治疗霍奇金淋巴瘤患者

Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.
PubMed 文献 · Blood · 2018-06-20

该先导试验采用非病毒RNA电转的CD19 CAR-T细胞(CART19)治疗复发或难治性经典型霍奇金淋巴瘤(cHL),假设清除肿瘤微环境中的CD19阳性B细胞及可能的循环CD19阳性HRS克隆细胞可间接影响不表达CD19的HRS细胞。5例入组患者均成功制备非病毒RNA CART19,4例按方案规定剂量输注,无严重毒性,可见缓解但为暂时性。

要点

  • 5例复发或难治性cHL患者均成功制备非病毒RNA CART19,4例按方案规定剂量输注
  • 未观察到严重毒性
  • 可见治疗反应,但均为暂时性

核心结论

  • 非病毒RNA CART19在复发或难治性cHL中未见严重毒性,可见缓解但为暂时性;据作者所知,这是首个使用非病毒RNA基因递送的CART19临床试验。

研究设计与样本

  • 先导试验,采用非病毒RNA CART19治疗复发或难治性经典型霍奇金淋巴瘤患者;5例入组,4例按方案规定剂量输注;试验注册号NCT02277522(成人)和NCT02624258(儿童)。

主要发现

  • 5例入组患者均成功制备非病毒RNA CART19,其中4例按方案规定细胞剂量输注。
  • 未出现严重毒性。
  • 可见治疗反应,但均为暂时性。

关键数值与推荐

  • 使用非病毒RNA CART19细胞,预期CAR蛋白仅表达数天,不同于病毒载体转导的CART19可在体内扩增并持续表达CAR。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR)-modified T cells are being investigated in many settings, including classical Hodgkin lymphoma (cHL). The unique biology of cHL, characterized by scant Hodgkin and Reed-Sternberg (HRS) cells within an immunosuppressive tumor microenvironment (TME), may pose challenges for cellular therapies directly targeting antigens expressed on HRS cells. We hypothesized that eradicating CD19+ B cells within the TME and the putative circulating CD19+ HRS clonotypic cells using anti-CD19-directed CAR-modified T cells (CART19) may indirectly affect HRS cells, which do not express CD19. Here we describe our pilot trial using CART19 in patients with relapsed or refractory cHL. To limit potential toxicities, we used nonviral RNA CART19 cells, which are expected to express CAR protein for only a few days, as opposed to CART19 generated by viral vector transduction, which expand in vivo and retain CAR expression. All 5 enrolled patients underwent successful manufacturing of nonviral RNA CART19, and 4 were infused with protocol-specified cell dose. There were no severe toxicities. Responses were seen, but these were transient. To our knowledge, this is the first CART19 clinical trial to use nonviral RNA gene delivery. This trial was registered at www.clinicaltrials.gov as #NCT02277522 (adult) and #NCT02624258 (pediatric).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Svoboda J, Rheingold SR, Gill SI, et al. Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. Blood. 2018. PMID: 29925499. doi:10.1182/blood-2018-03-837609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。